Success examples
SMARCA2/4-Dependent Chromatin Remodelling Establishes Gene Regulatory Programs in Early Human Embryos and Blastoids

van Knippenberg S. S. F. A., Tryfonos M., De Busscher J., Solis M., Lorent C., Girard O., Poovathingal S., Wojno M., Khodeer S., De Clercq J., Mikorska A., Smeers I., Wigerinck E., Meynen Y., Voet T., David L., Van de Velde H., Pasque V.

bioRxiv 2025. 12.01.691499.

SMARCA2/4 PROTAC
DOI
Success examples
Nanoencapsulated senotherapeutic compounds targeting connexin-43 for enhanced wound healing

Rodríguez-Candela Mateos M., García-Fernández J., Saraiva S. M., Grimaudo M. A., Alijas S., Escudero A., Varela-Eirín M., Pérez Cano J., Acea Nebril B., Barrio L. C., Mayan M. D., de la Fuente M.

iScience 2026, Volume 29, Issue 2, 114547.

P38 MAPK Inhibitor
DOI
Success examples
p38 inhibition restores chemosensitivity of tumor cells by disrupting oligomerized breast cancer resistance protein membrane trafficking

Pan Y., Zhu Z., Zhu Y., Hu T., Zhang Z., Fan H., Yu S., Wei Z., Wang A., Lu Y., Chen W.

iScience. 2025, 29(1):114359.

P38 MAPK Inhibitor
DOI
PubMed
Success examples
Complementary roles and synergy of the Ephedra-Glycyrrhiza herb pair across murine models of respiratory symptoms and poly(I:C)-induced pneumonia

Zhang F., Ma Y., Mei J., Xie X., Wang X., Zhang Y., Yu B.

Phytomedicine. 2026, 151:157795.

P38 MAPK Inhibitor
DOI
PubMed
Success examples
Tissue-Slice Organ-on-Chip Culture of Hypothalamic and Pituitary of Lambs - The Role of Phoenixin-20 as a Modulator of Gonadotrophic Axis

Szlis M., Przybył B. J., Wójcik-Gładysz A.

ACS Biomater Sci Eng. 2026, 12(2):1045-1058.

NPY1R Antagonist
DOI
PubMed
Success examples
Multiomic integration reveals tumoral heterogeneity of lipid dependence within lethal group 3 medulloblastoma

Bernardi F., Torrejon J., Basili I., Van Ommeren R., Marsaud V., Yu H., Talbot J., Souphron J., Indersie E., Forget A., Bonneau B., Massiot A., Alcazar C., Figeac L., Bonerandi E., Cancila G., Sirbu O., Yadav N., Mohanakrishnan D., Lombard B., Loew D., Poullet P., Liva S., Lovino M., Lin I-H., Nakashima T., Gharsalli T., Nicolas P. A., Yubuki N., Ribas R. A., Colsch B., Chu-Van E., Castelli F., Sampaio J. L., Leboucher S., Lasgi C., Besse L., Soler M-N., Lo Re V., Planque N., Abeysundara N., Balin P., Wang H., Su H., Wu X., Cavalli F. M. G., Saulnier O., Ficarra E., Di Marcotullio L., Kumegawa K., Maruyama R., Kawauchi D., Picard D., Remke M., Riffaud L., Puiseux C., Bouchoucha Y., Huybrechts S., Simbozel M., Bourdeaut F., Varlet P., Puget S., Blauwblomme T., Andrianteranagna M., Masliah Planchon J., Dugourd A., Saez-Rodriguez J., Barillot E., Servant N., Martignetti L., Rich J., Kool M., Pfister S. M., Agnihotri S., Suzuki H., Fanjul M., Wang W-J., Tsai J-W., Sun R. C., Beccaria K., Dufour C., Sarry J-E., Michealraj K. A., Taylor M. D., Ayrault O.

Cancer Cell. 2026, 44(2):383-404.e18.

FAS inhibitor
DOI
PubMed